Phase 1 Completed N=13 Treatment

The Maraviroc Central Nervous System (CNS) Study

Source: ClinicalTrials.gov NCT00982878 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2019

Primary outcomePrimary: CSF (Cerebrospinal Fluid) : Plasma Ratio of Maraviroc 1H Magnetic Resonance Spectroscopy (1H-MRS) — 1.01 ratio

Summary

The purpose of this study is to describe the Central Nervous System exposure of maraviroc in HIV-1 infected subjects receiving a stable antiretroviral regimen, including maraviroc, at steady state.

Outcome Measures

Outcome	Result	p-value
PRIMARY CSF (Cerebrospinal Fluid) : Plasma Ratio of Maraviroc 1H Magnetic Resonance Spectroscopy (1H-MRS)	1.01	—
SECONDARY Number of Participants With Adverse Events	—	—

Eligibility Criteria

Inclusion Criteria

HIV-1 infected males or females
signed informed consent
plasma HIV RNA 32
Contraindication to lumbar puncture examination. Such as:
Existing neurological diseases
Bleeding disorders

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00982878). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.